Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd. (NLSP) generates news that reflects both its historical role as a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders and its transformation through a merger with Kadimastem Ltd. into NewcelX Ltd. Company announcements and SEC filings describe a shift from a pure CNS small-molecule focus toward an integrated platform that also encompasses cell therapies for neurodegenerative and metabolic diseases.
News items associated with NLSP and the subsequent NewcelX name cover several recurring themes. Transaction-related updates include the approval and closing of the merger with Kadimastem, the 1-for-10 reverse share split, the name change to NewcelX Ltd., and the transition of the Nasdaq listing from NLSP to the new symbol NCEL. These releases explain the exchange ratio between NLS and Kadimastem shareholders, the resulting ownership structure, and the rationale for combining small-molecule and cell therapy pipelines.
Pipeline and R&D news highlights programs such as AstroRx® for ALS, the IsletRx stem cell–derived therapy for insulin-dependent diabetes, and the DOXA small-molecule platform for CNS and neurodegenerative indications. Announcements describe preclinical and clinical milestones, intellectual property developments such as a Hong Kong patent for IsletRx-related cell-selection and enrichment technology, and expansion of the DOXA platform through the AEX-6xx series developed with Aexon Labs.
Additional coverage includes strategic collaborations and governance updates. Examples are the collaboration framework between Kadimastem and TargetGene for gene-edited cell therapies, continued support from the BIRD Foundation for the ITOL-102 diabetes program, and appointments to leadership roles and the Scientific Advisory Board at NewcelX. For readers tracking NLSP-related news, this page offers a consolidated view of historical NLS announcements and the ongoing evolution of the combined company under the NewcelX name and NCEL ticker.
NewcelX (Nasdaq: NCEL) announced on November 17, 2025 the appointment of Prof. Jeremy Shefner, MD, PhD, to its Scientific Advisory Board.
Prof. Shefner is Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute and is an ALS and neuromuscular disorder specialist with more than 200 peer-reviewed papers and co‑founder status of the Northeast ALS Clinical Trials Consortium (NEALS).
He will advise on NewcelX's ALS programs, including clinical development of AstroRx, and support integration of neuromuscular and neurodegenerative expertise into the company's cell‑therapy and neuroscience platform.
NLS Pharmaceutics (NASDAQ:NLSP) and Aexon Labs expanded the DOXA platform with the AEX-6xx small-molecule series targeting arousal stability, cognition, and neuroprotection. Lead compound AEX-635 also modulates MRP1, which may aid neuroprotection and CNS bioavailability. The companies reported robust preclinical efficacy (up to 80% cataplexy reduction; >70% wakefulness increase) and plan IND-enabling studies. Financing includes ~$7M equity raised and a $25M equity line of credit, supporting operations for at least 12 months. Patents WO2024141660 and WO2024115797 are in national phases. NewCelX formation follows merger completion.
NLS Pharmaceutics (Nasdaq: NLSP) and Kadimastem announced that, following their merger completed as of Oct 29, 2025, the combined company NewCelX will continue development of the ITOL-102 Type 1 Diabetes cell therapy program with ongoing support from the BIRD Foundation.
The ITOL-102 program remains partnered with iTolerance and aims to develop a stem-cell-derived pancreatic islet therapy that avoids lifelong immunosuppression. The BIRD Foundation — which has invested >$300M in >1,000 joint projects generating >$10B in sales since 1977 — confirmed continued support under NewCelX's development framework.
NLS Pharmaceutics (NASDAQ: NLSP / NLSPW) announced a 1-for-10 reverse share split effective in Switzerland on October 30, 2025, with Nasdaq reflecting the split at market open on October 31, 2025. Following the anticipated merger with Kadimastem, the company will change its name and trade under the new symbol NCEL. The new post‑merger CUSIP is H5835A109.
The amended capital structure lists total share capital of CHF 282,908.80, a capital band allowing issuance up to 2,859,412 common shares, conditional capital provisions, and specific outstanding share counts and warrant figures after the transactions.
NLS Pharmaceutics (NASDAQ: NLSP / NLSPW) and Kadimastem (TASE: KDST) announced that all material conditions precedent for their merger have been satisfied or waived, and the merger closing is set for October 30, 2025. Nasdaq approved listing of the combined company's common shares.
The combined company will be named NewCelX Ltd. and listed on the Nasdaq Capital Market under the ticker NCEL beginning October 31, 2025. Kadimastem trading on TASE will be suspended and its final delisting is scheduled for October 31, 2025.
The final exchange ratio is 7.06 NLS common shares per Kadimastem share, which after a 1-for-10 reverse split of NLS shares becomes 0.706 NLS common shares per Kadimastem share. NewCelX shares are expected to be deposited to Kadimastem shareholders' accounts by the end of day November 3, 2025, with trading availability expected November 4, 2025 or soon thereafter.
NLS Pharmaceutics (Nasdaq: NLSP) and Kadimastem announced an MOU between Kadimastem and TargetGene to jointly develop next-generation gene-edited cell therapies, combining Kadimastem's AstroRx and IsletRx platforms with TargetGene's DNA-guided gene-editing technology.
The collaboration will operate under the combined company NewCelX upon completion of the anticipated merger between NLS and Kadimastem. The MOU frames joint R&D, technology exchange, and potential future licensing to enhance therapeutic performance, stability, and safety with a goal of scalable, curative cell-based treatments.
NLS Pharmaceutics (Nasdaq: NLSP / NLSPW) and Kadimastem (TASE: KDST) received Nasdaq approval for the combined company to list as NewCelX (NCEL) following the closing of their merger, expected on October 30, 2025, with trading under the new name to begin October 31, 2025, subject to customary closing conditions.
The approved exchange ratio yields Kadimastem shareholders ~84.4% ownership and NLS shareholders ~15.6% of the combined company; post-reverse split, each Kadimastem share equals ~0.62 NLS shares. Kadimastem ordinary shares are expected to be delisted from TASE around the closing. Warrant trading will not continue post-merger.
NewCelX will continue clinical programs: AstroRx Phase 2a for ALS and IsletRx pre-IND work toward a Phase 1 diabetes trial; technology transfer and GMP manufacturing setup with Pluri completed.
NLS Pharmaceutics (NASDAQ: NLSP) shareholders have approved the merger with Kadimastem (TASE: KDST) at an Extraordinary General Meeting on September 29, 2025. The combined company will be renamed NewCelX Ltd. and trade on Nasdaq under the ticker "NCEL".
Under the approved terms, Kadimastem shareholders will own 84.4% of the combined company, while NLS shareholders will retain 15.6%. The merger unites Kadimastem's cell therapy programs, including a Phase 2a ALS study of AstroRx® and IsletRx diabetes program, with NLS's CNS small-molecule expertise. Ronen Twito will serve as Executive Chairman & CEO, while Prof. Michel Revel, Kadimastem's founder and developer of the successful MS drug Rebif®, will become Chief Scientific Officer.
NLS Pharmaceutics (NASDAQ:NLSP) and Kadimastem (TASE:KDST) announced the SEC's approval of their Form F-4 registration statement for their planned merger. The combined entity will be named NewCelX Ltd. and trade on Nasdaq as "NCEL".
The merger will unite Kadimastem's cell therapy platforms with NLS's small-molecule expertise. Key programs include Kadimastem's AstroRx®, preparing for Phase 2a trials in ALS, and IsletRx, a stem cell-derived therapy for insulin-dependent diabetes developed with iTolerance. The extraordinary general meeting is scheduled for September 29, 2025.
NLS Pharmaceutics (NASDAQ:NLSP) and its merger partner Kadimastem have secured a significant patent in Hong Kong for their cell selection and enrichment technology used in developing IsletRx, a stem cell-derived therapy targeting insulin-dependent diabetes. The patent complements existing protections in Europe, the United States, and India.
The technology enables the selection of highly functional islet cells from differentiated cell populations to maximize therapeutic effect. Hong Kong represents a strategic market with approximately 706,000 adults living with diabetes (8.2% prevalence) and an estimated economic impact of $90 billion, based on average lifetime healthcare expenditures of $125,000 per patient.
FAQ
What is the current stock price of Nls Pharmaceutics (NLSP)?
What is the market cap of Nls Pharmaceutics (NLSP)?
